Navigation Links
Morelli receives AACR fellowship for research in metastatic colorectal cancer
Date:4/15/2013

The University of Texas MD Anderson Cancer Center, accepted the one-year, $50,000 grant at the AACR Annual Meeting 2013 grants reception and dinner. The award is one of six granted to MD Anderson researchers and faculty at the meeting.

The Fight Colorectal Cancer-AACR Fellowship, in memory of Lisa Dubow, represents a joint effort to encourage and support a postdoctoral or clinical research fellow conducting translational or clinical research on therapeutic approaches for late stage colorectal cancer. The grant supports a project designed to lead to individualized treatment options for patients.

Colorectal cancer is the fourth common cancer diagnosed in the United States each year. The National Cancer Institute estimates 142,820 new cases of colon or rectal cancer bill be diagnosed in 2013, and 50,830 patients will die of the disease.

Over the last decade, the development of anti-epidermal growth factor receptor monoclonal antibodies, such as cetuximab and panitumumab, has improved the clinical outcomes in metastatic colorectal cancer patients who don't have KRAS mutations. Yet, not all of these select patients obtain clinical benefits, and refinement of the predictive biomarker is necessary, says Scott Kopetz, M.D., Ph.D., associate professor in MD Anderson's Department of Gastrointestinal Medical Oncology.

"A patient's tumor is composed of many variations of always-changing cancer cells," said Kopetz, Morelli's mentor. "Standard methods don't capture the current state of the cancer at the time that treatment is started. With recently developed techniques, the patient's blood can provide an increasingly transparent window into the current inter-workings of the cell, allowing better selection of chemotherapy treatments."

Morelli's project will aim to answer specific clinical research questions relevant to the biology of colorectal cancer, and provide insights that may advance the care of patients in the near future.

"Specifically, we will focus on two critical aspects of tumor biology that are anticipated to have profound clinical outcomes: the recognition that both tumor heterogeneity and the acquired mutations in KRAS and EGFR play a substantial role in determining resistance to chemotherapy," Morelli said.

Lisa Dubow was 42 years old when she was diagnosed with Stage III colorectal cancer, which later recurred. A founder of the Fight Colorectal Cancer, Dubow also worked for the "Lisa Fund," which supports researchers and is dedicated to improving therapies and outcomes for patients with late-stage disease.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. The Law Office of Wolf & Pravato, The Alters Firm and Morelli Ratner File Class Action Lawsuit Against Global Spray Foam Manufacturer
2. Christopher Jayne, M.D., Receives InTone Specialist Certification To Treat Female Urinary Incontinence From InControl Medical, LLC
3. Local Female Clinical Research Executive Receives Industry Distinction as an Innovator for Change
4. Tosh Patterson Receives Honors at the 5th Annual Get RADICAL Women’s Conference Featuring Jillian Michaels, Lisa Nichols, Giuliana Rancic
5. Vincent R. Lucente, MD, MBA, Miles Murphy, MD, Nina Bhatia, MD, and Valerie Schissler, MSN, CRNP, Receives InTone Specialist Certification
6. Advanced Mold Diagnostics Receives Angie's List Super Service Award for 4th Straight Year
7. BU student receives 2013 Joanna M. Nicolay Melanoma Foundation scholarship award
8. UC Davis MIND Institute receives prestigious Autism Centers of Excellence Award
9. Citel’s Portico™ TVA™ Receives Updated Validation from BroadSoft
10. Kessler Foundation scientist receives National MS Society grant for predictors of memory decline
11. Port Washington, NY Dentist Dr. Doron Keren of Gold Coast Family Dental Receives 98 Percent Satisfaction Rating from Patient Reviews
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Texas (PRWEB) , ... February 09, 2016 , ... ... reconstruction firm helping businesses recover after a disaster, announced today the acquisition of ... companies in Hawaii. , “Investing in like-minded companies who excel at ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore ... help enterprises move workloads to the cloud. Cirracore provides a secure VMware® ... without traversing the Internet. Transformation Solutions (TSL Partners) provides a full range ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul ... appointment after they noticed their furnace not producing any heat. Shortly after entering the ... cracked heat exchanger was leaking dangerous levels of carbon monoxide into the home, at ...
(Date:2/9/2016)... California (PRWEB) , ... February 09, 2016 , ... ... of their new nationwide service to expand access to affordable hearing aids ... million hard of hearing individuals in the United States. , “For the average ...
(Date:2/9/2016)... ... February 09, 2016 , ... United ... In Praise of Prevention,” an animated video designed to prevent the ... translations of the video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
(Date:2/8/2016)... -- Respiratory Devices - Medical Devices Pipeline Assessment, ... report, " Respiratory Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. The report ... comparative analysis of the products at various stages ... in the pipeline product development. It also provides ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , Feb. 8, ... Pharmaceuticals, Inc. (Medimetriks) today announced that they have entered ... commercialization rights for OPA-15406 in the U.S. and ... manufacturing rights.  OPA-15406 is a topical, non-steroidal phosphodiesterase IV ... --> --> In ...
Breaking Medicine Technology: